Murakami et al., also provide a strategy for targeting epidermal growth factor receptor variant III (EGFR vIII) and inducing antitumor activity in GBM cells using a new NK cell line containing a chimeric immune antigen receptor (CAR-KHYG-1) [252]. The gene discussed is EGFR; the disease is glioblastoma.